Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Celgene Corp (NASDAQ:CELG)

97.89
Delayed Data
As of Feb 05
 -4.04 / -3.96%
Today’s Change
92.98
Today|||52-Week Range
140.72
-18.26%
Year-to-Date
ImmunoGen/Merck Collaborate for Ovarian Cancer Study
Feb 05 / Zacks.com
AbbVie Posts In-Line Earnings, Maintains 2016 Outlook
Jan 29 / Zacks.com
Why Did Biotech Fall Off a Cliff in January?
Feb 04 / MotleyFool.com
SurModics' (SRDX) Q1 Earnings & Revenues Beat Estimates
Jan 29 / Zacks.com
Synthetic Biologics Tanks on Unfavorable Trimesta Data
Feb 03 / Zacks.com
Stock Market News for January 29, 2016
Jan 29 / Zacks.com
Alexion Misses on Earnings and Revenues in Q4, Gives View
Feb 03 / Zacks.com
Amgen Tops on Q4 Earnings & Revenues, Ups 2016 Outlook
Jan 29 / Zacks.com
Merck Tops on Q4 Earnings, Revenue Outlook Falls Short
Feb 03 / Zacks.com
Biotech ETF (IBB) Hits New 52-Week Low
Jan 29 / Zacks.com
Why NantKwest Shares Fell 41% in January
Feb 02 / MotleyFool.com
Celgene's Earnings Miss Pales in Comparison to Wall Street's Miss
Jan 29 / MotleyFool.com
Avalanche (AAVL) Set to Acquire Annapurna Therapeutics
Feb 02 / Zacks.com
Incyte Halts Phase II Jakafi-Stivarga Combination Study
Jan 28 / Zacks.com
Exelixis' Cabozantinib Positive in Renal Cell Carcinoma Study
Feb 02 / Zacks.com
Abbott Labs (ABT) Beats on Q4 Earnings, Lags on Revenues
Jan 28 / Zacks.com
Abbott Labs to Boost Diagnostics Business with Alere Buyout
Feb 02 / Zacks.com
Top Biotechs for 2016
Jan 28 / MotleyFool.com
How to Use a Stock Market Crash to Your Advantage
Feb 02 / MotleyFool.com
Celgene Misses on Q4 Earnings, Reiterates 2016 Guidance
Jan 28 / Zacks.com
Start the New Year off Right with 3 Best Biotech Stocks
Feb 02 / MotleyFool.com
Bristol-Myers Beats on Q4 Earnings, Provides 2016 Guidance
Jan 28 / Zacks.com
Pfizer Beats on Q4 Earnings, Revenues, Outlook Disappoints
Feb 02 / Zacks.com
Celgene (CELG) Misses on Q4 Earnings, Beats on Revenues
Jan 28 / Zacks.com
Credit Suisse Picks 7 Health Care Stocks to Own for the Next 6 Months
Feb 02 / TheStreet.com
Vertex (VRTX) Posts Narrower 4Q Loss, Maintains Outlook
Jan 28 / Zacks.com
Spectrum (SPPI) Initiates Phase III Study on SPI-2012
Feb 01 / Zacks.com
The Big Question for Celgene Corporation's Management
Jan 27 / MotleyFool.com
3 Biotech Stocks You Don't Have to Babysit
Feb 01 / MotleyFool.com
3 Healthcare Stocks You Don't Have to Babysit
Jan 27 / MotleyFool.com
Two ETF Plays for When Biotech Stocks Rebound
Feb 01 / TheStreet.com
Biogen Tops on Q4 Earnings by a Wide Margin, Provides View
Jan 27 / Zacks.com
Jim Cramer: Stop Thinking So Short Term About Biotech Stocks
Feb 01 / TheStreet.com
Celgene (CELG) to Report Q4 Earnings: What to Expect?
Jan 26 / Zacks.com
3 Stocks Pulling The Drugs Industry Downward
Feb 01 / TheStreet.com
The 1 Biotech Stock I Want to Own in 2016
Jan 26 / MotleyFool.com
Biotech String: Assessing the January Damage, Gilead's Bottoming P/E, Sarepta Panel D...
Feb 01 / TheStreet.com
Celgene Reveals Data on Second-Line Abraxane-Gemzar
Jan 25 / Zacks.com
Biotech Billionaire Launches His Most Auspicious Project Yet
Jan 31 / MotleyFool.com
Will 2016 Be Celgene Corporation's Best Year Yet?
Jan 25 / MotleyFool.com
Celgene (CELG) Earnings Report: Q4 2015 Conference Call Transcript
Jan 30 / TheStreet.com
What You Missed at the 2016 J.P. Morgan Healthcare Conference
Jan 24 / MotleyFool.com
Bristol-Myers' Daklinza-Sovaldi Label Expanded in the EU
Jan 29 / Zacks.com
Gilead Takes a Page Out of Celgene's Playbook
Jan 23 / MotleyFool.com
5 Stocks to Buy and Hold for the Next Decade
Jan 29 / MotleyFool.com
Pharma sell-off threatens to stifle appetite for IPOs
Jan 18 / FT.com
Corcept Reports Preliminary Q4 Earnings, Revenues in Line
Jan 29 / Zacks.com
McKesson slides on generic drugs unit weakness
Jan 11 / FT.com
Roche's (RHHBY) Earnings Miss Estimates, Revenues Beat
Jan 29 / Zacks.com
Big pharma joins forces to tackle cancer
Jan 11 / FT.com